CN101503355B - Synthesis and refining of triflusal - Google Patents
Synthesis and refining of triflusal Download PDFInfo
- Publication number
- CN101503355B CN101503355B CN2009100009096A CN200910000909A CN101503355B CN 101503355 B CN101503355 B CN 101503355B CN 2009100009096 A CN2009100009096 A CN 2009100009096A CN 200910000909 A CN200910000909 A CN 200910000909A CN 101503355 B CN101503355 B CN 101503355B
- Authority
- CN
- China
- Prior art keywords
- purified water
- stirring
- dry
- drained
- wet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RMWVZGDJPAKBDE-UHFFFAOYSA-N 2-acetyloxy-4-(trifluoromethyl)benzoic acid Chemical compound CC(=O)OC1=CC(C(F)(F)F)=CC=C1C(O)=O RMWVZGDJPAKBDE-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 238000007670 refining Methods 0.000 title claims abstract description 19
- 229960002268 triflusal Drugs 0.000 title abstract description 5
- 230000015572 biosynthetic process Effects 0.000 title description 3
- 238000003786 synthesis reaction Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 57
- 230000008569 process Effects 0.000 claims abstract description 28
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 15
- 239000011630 iodine Substances 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 88
- 239000008213 purified water Substances 0.000 claims description 62
- 238000003756 stirring Methods 0.000 claims description 54
- 238000006243 chemical reaction Methods 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 238000001035 drying Methods 0.000 claims description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 238000011010 flushing procedure Methods 0.000 claims description 33
- 238000010907 mechanical stirring Methods 0.000 claims description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 25
- 238000005406 washing Methods 0.000 claims description 25
- 239000012065 filter cake Substances 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 206010013786 Dry skin Diseases 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 17
- -1 trifluoromethyl Whitfield's ointment Chemical compound 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 11
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 9
- 230000008025 crystallization Effects 0.000 claims description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000005457 ice water Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 238000004383 yellowing Methods 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 5
- 239000012346 acetyl chloride Substances 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 229960001701 chloroform Drugs 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000003054 catalyst Substances 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 50
- 238000004128 high performance liquid chromatography Methods 0.000 description 28
- 238000000746 purification Methods 0.000 description 21
- 239000000356 contaminant Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100009096A CN101503355B (en) | 2009-01-21 | 2009-01-21 | Synthesis and refining of triflusal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100009096A CN101503355B (en) | 2009-01-21 | 2009-01-21 | Synthesis and refining of triflusal |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101503355A CN101503355A (en) | 2009-08-12 |
CN101503355B true CN101503355B (en) | 2012-05-09 |
Family
ID=40975748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100009096A Active CN101503355B (en) | 2009-01-21 | 2009-01-21 | Synthesis and refining of triflusal |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101503355B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103709183B (en) * | 2013-12-06 | 2016-01-06 | 辽宁师范大学 | The synthetic method of triflusal-metal compound |
CN103665012B (en) * | 2013-12-06 | 2016-06-22 | 辽宁师范大学 | Novel triflusal inorganic drug compound and synthetic method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1680266A (en) * | 2005-01-11 | 2005-10-12 | 山东师范大学 | Catalytic synthesis of 4-trifluoromethylvinyl salicylic acid |
CN101177398A (en) * | 2007-12-11 | 2008-05-14 | 南京海陵中药制药工艺技术研究有限公司 | Method for refining trifluoro willow |
-
2009
- 2009-01-21 CN CN2009100009096A patent/CN101503355B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1680266A (en) * | 2005-01-11 | 2005-10-12 | 山东师范大学 | Catalytic synthesis of 4-trifluoromethylvinyl salicylic acid |
CN101177398A (en) * | 2007-12-11 | 2008-05-14 | 南京海陵中药制药工艺技术研究有限公司 | Method for refining trifluoro willow |
Also Published As
Publication number | Publication date |
---|---|
CN101503355A (en) | 2009-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101279997B (en) | Novel preparation of budesonide | |
CN102367262B (en) | Preparation method of hydrocortisone | |
CN106589037A (en) | Method for preparing progesterone and derivatives thereof | |
CN102395591B (en) | Method for preparing prasugrel | |
CN101503355B (en) | Synthesis and refining of triflusal | |
CN102002031A (en) | Full chemical synthesis method for mangiferin aglycones | |
CN104744540A (en) | Preparation method for regadenoson | |
CN109867685B (en) | Preparation method of clopidogrel hydrogen sulfate II type | |
CN103304467B (en) | Single stage method prepares the method for N-caffeoyl tryptamines | |
CN103435592A (en) | 2-((4R,6S)-6-formaldehyde-2,2-dimethyl-1,3 dioxane-4-base)-methyl acetate preparation method | |
CN101759740A (en) | Method for synthesizing 3-alpha-acetoxy-deoxidized androstane-5-17-ketone | |
CN106589035A (en) | Preparation process of prednisolone acetate | |
CN103304623B (en) | Synthetic method of 6[beta],19-epoxy androstane-3,17-dione | |
CN109020933B (en) | Method for purifying mycophenolic acid | |
CN1563003A (en) | Suitable industrialized method of preparing Lamivudine | |
CN110845562B (en) | Method for recycling betamethasone or dexamethasone synthetic mother liquor material | |
CN107540640A (en) | A kind of reductive modification agent and its preparation method and application | |
CN109134577B (en) | Synthetic method of 3 alpha-hydroxy-5 alpha-cholanic acid | |
CN101402660B (en) | Synthesis method for glucose tetra-ester in tobacco | |
CN102276508A (en) | Low-cost functional monomer containing polymerizable double bonds and mercapto chain transfer and preparation method thereof | |
CN101220073B (en) | Synthesis of polyhydroxy ocean steroid (25R)-5 alpha-cholesteric-2 beta,3 alpha,26-triol | |
CN101792434B (en) | Preparation method of tetra-acylated puerarin | |
CN112142595B (en) | Preparation method and purification method of ethyl 2,4, 5-trifluoro-benzoylacetate | |
CN1321128C (en) | Preparation method of pregna-4-ene-7, 21-dicarboxylic acid, 9, 11-epoxy-17-hydroxy-3-oxo, gamma-lactone, methyl ester, (7 alpha, 11 alpha, 17 alpha) | |
CN107652987B (en) | Preparation method of maleic acid cholesterol monoester group citric acid triester liquid crystal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JILIN TIANQIANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING OLELAND PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CENTER Effective date: 20100108 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20100108 Address after: Liuhe County People's Avenue in Tonghua city of Jilin province No. 309 post encoding: 135300 Applicant after: Jilin Tianqiang Pharmaceutical Co.,Ltd. Address before: Room 215, room 3, A 4, Yongding Road, Beijing, Haidian District, China: 100039 Applicant before: Beijing Oleland Medical Technology Development Center |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: DIAOYUTAI PHARMACEUTICAL GROUP JILING TIANQIANG PH Free format text: FORMER OWNER: JILIN TIANQIANG PHARMACEUTICAL CO., LTD. Effective date: 20140410 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140410 Address after: The people of the street 135300 Liuhe County of Jilin province Liuhe Town, No. 309 Patentee after: DIAOYUTAI MEDICAL GROUP JILIN TIANQIANG PHARMACEUTICAL Co.,Ltd. Address before: The people of the street 135300 Tonghua City Liuhe County Jilin province No. 309 Patentee before: Jilin Tianqiang Pharmaceutical Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Synthesis and refinement of trifoliate willow Granted publication date: 20120509 Pledgee: Jilin Bank Co.,Ltd. Tonghua Liuhe Branch Pledgor: DIAOYUTAI MEDICAL GROUP JILIN TIANQIANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2024220000126 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |